Anti-VEGF antibodies

An antibody and carrier technology, applied in the direction of antibodies, anti-inflammatory agents, anti-tumor drugs, etc.

Active Publication Date: 2010-12-15
GENENTECH INC
View PDF206 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The precise mechanisms governing the angiogenic transition are not understood, but neovascularization of the tumor mass is thought to result from a net balance of many angiogenic stimulators and inhibitors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-VEGF antibodies
  • Anti-VEGF antibodies
  • Anti-VEGF antibodies

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0323] Preparation of Antibody Drug Conjugates

[0324] In an antibody drug conjugate (ADC), an antibody is coupled to one or more drug moieties (D), eg, about 1 to about 20 drug moieties per antibody, via a linker (L). ADCs of general formula I can be prepared in several ways using organic chemistry reactions, conditions and reagents known to those skilled in the art, including: (1) reaction of the nucleophilic group of the antibody with a divalent linking reagent A valent bond forms Ab-L, which then reacts with the drug moiety D; and (2) the nucleophilic group of the drug moiety reacts with a divalent linker to form D-L via a covalent bond, which then reacts with the nucleophilic group of the antibody. Additional methods for preparing ADCs are described herein.

[0325] Ab-(L-D) p I

[0326] A linker may consist of one or more linker components. Exemplary linker components include 6-maleimidocaproyl ("MC"), maleimidopropanoyl ("MP"), valine-citrulline (" val-ci...

Embodiment 1

[0489] Generation and characterization of anti-VEGF antibodies

[0490] Construction of a synthetic phage antibody library (humanized anti-ErbB2 antibody, 4D5) on a single framework by introducing diversity in the complementarity determining regions (CDRs) of the heavy and light chains (Lee, C.V. et al. J Mol Biol 340 , 1073-93 (2004)). Briefly, a phage-displayed synthetic polypeptide library was constructed on a single human framework by introducing synthetic diversity at the solvent-exposed positions of the heavy chain complementarity determining regions (CDRs). To improve library performance, monovalent and bivalent antigen-binding fragment (Fab) libraries were constructed, and different CDR-H3 diversity was investigated by varying amino acid composition and CDR length. The library was then expanded by increasing the variability in CDR-H3 length and utilizing custom codons that mimic the amino acid composition of native CDR-H3 sequences. High affinity antibodies were gene...

Embodiment 2

[0493] Anti-VEGF Antibody Binding Affinity

[0494] To determine the binding affinity of anti-VEGF IgG, BIAcore TM The -3000 device performs Surface Plasmon Resonance (SRP) measurements. Carboxymethylated dextran biosensor chips (CM5, BIACORE, Inc.) were treated with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide according to the supplier's instructions. (EDC) and N-hydroxysuccinimide (NHS) activation. Human or murine VEGF was immobilized to achieve approximately 60 response units (RU) of coupled protein. see Figure 10 . For kinetic measurements, two-fold serial dilutions of anti-VEGF IgG (7.8 nM to 500nM). Association rate (k on ) and dissociation rate (k off ) using the bivalent binding model (BIACORE Evaluation software, version 3.2) calculations. Calculate the equilibrium dissociation constant (Kd) as k off / k on ratio.

[0495] Since the off-rate of B20.4.1 was not measurable, IgG was immobilized to achieve approximately 1000 response units (RU) of coupled...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies.

Description

field of invention [0001] The present invention generally relates to anti-VEGF selected polypeptide sequences and antibodies having beneficial properties for research, therapeutic and diagnostic purposes. Background of the invention [0002] The development of the vascular system is a fundamental requirement for many physiological and pathological processes. Actively growing tissues such as embryos and tumors require an adequate blood supply. They meet this need by producing pro-angiogenic factors that promote the formation of new blood vessels through a process called angiogenesis. Angiogenesis is a complex but ordered biological event that includes all or many of the following steps: a) proliferation of endothelial cells (ECs) from existing ECs or differentiation from progenitor cells; b) migration and coalescence of ECs to form cord-like structure; c) the vascular cord then undergoes tubulogenesis to form a vessel with a central lumen; d) the existing vascular cord or v...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/00C07K16/22C07K16/32A61K39/395A61P35/00C12N15/13
CPCC07K16/005C07K16/22C07K2317/565C07K2317/92C07K16/32A61K2039/505C07K2317/73C07K2317/56C07K2316/96A61P17/06A61P19/02A61P29/00A61P35/00A61P35/04A61P43/00A61P9/00A61P9/10A61K39/395C07K16/00G01N33/6893G01N2333/475
Inventor 热尔梅娜·富重伟·V·李
Owner GENENTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap